World’s First Personalized mRNA Cancer Vaccine Succeeds in Phase 3 Trial, Marking a New Era in Cancer Treatment
For decades, cancer treatment has largely followed a common approach: identify the type of cancer and then give patients treatments designed for that disease. But a new generation of cancer therapy is moving toward something much more personal—treatment designed around the unique genetic features of an individual patient’s tumor. Now, pharmaceutical and biotechnology company Moderna, working with Merck, has reported encouraging Phase 3 results for a personalized mRNA cancer vaccine called intismeran autogene , also known as mRNA-4157/V940 . The therapy is designed specifically for each patient and can target up to 34 tumor-specific mutations . The latest results could represent an important step toward making personalized cancer vaccines a practical treatment option, particularly for people with high-risk melanoma. A Cancer Vaccine Built for Each Patient Unlike traditional vaccines, which are generally designed to protect people against the same infectious disease, intismeran is create...